The retina is technically part of the brain. It develops from the same tissue, its ganglion cells send axons directly into the skull as the optic nerve, and those cells are among the most energy-hungry in the body. That makes the retina an obvious place to test a compound that acts on mitochondrial energy production, and researchers have done exactly that. The results are consistent and encouraging, and they are almost entirely in animals.
Key Takeaways
- Retinal ganglion cells have extremely high energy demand and, once lost, do not regenerate. That combination makes them a logical target for mitochondrial interventions.
- A 2009 study reported behavioural and metabolic neuroprotection against optic neuropathy in an animal model.
- A 2012 study found methylene blue protected primary rat retinal ganglion cells from cellular senescence in culture.
- A 2020 study reported improved survival and regeneration-associated marker expression after optic nerve transection in rats.
- A 2025 study reported a neuroprotective effect in a rat model of traumatic optic neuropathy.
- Four consistent studies, and not one of them is a human trial. There is no clinical evidence for methylene blue in any human eye disease.
Why the Eye Is a Reasonable Place to Look
Retinal ganglion cells sit at the end of a long chain of visual processing and send their axons all the way to the brain. Maintaining that axon, and firing constantly in response to light, costs a great deal of ATP. Mitochondria are packed densely in these cells, particularly at the optic nerve head.
That energy dependence shows up clinically. Several optic neuropathies are explicitly mitochondrial diseases, and glaucoma research has increasingly implicated mitochondrial dysfunction alongside intraocular pressure. If a compound genuinely improves mitochondrial electron transport, retinal ganglion cells are where you would expect it to matter most.
Methylene blue’s proposed mechanism fits. At low concentrations it can accept electrons and pass them to cytochrome c, effectively providing an alternative route around a congested electron transport chain.
What the Studies Found
A 2009 study reported that methylene blue provided behavioural and metabolic neuroprotection against optic neuropathy, combining functional outcomes with metabolic measurement[1]. Behavioural endpoints matter because they test whether the animal can actually see, not only whether cells survived a count.
A 2012 study took a cellular approach, showing methylene blue protected primary rat retinal ganglion cells from senescence in culture[2]. Senescent cells are alive but no longer functioning normally, and senescence is thought to contribute to age-related retinal decline.
A 2020 study used optic nerve transection, a deliberately severe model, and reported that methylene blue promoted ganglion cell survival and increased expression of GAP-43, a protein associated with axonal regeneration[3]. That is a more ambitious claim than survival alone, since the mammalian optic nerve does not normally regenerate.
A 2025 study reported neuroprotection in a rat model of traumatic optic neuropathy[4], extending the pattern into acute injury.
How to Weigh Four Consistent Animal Studies
Consistency across independent groups, different injury models, and both cell culture and whole animals is genuinely a point in favour. Fragile findings tend not to replicate across that much variation.
It is still preclinical work, and preclinical neuroprotection has an exceptionally poor record of translating. The graveyard of agents that protected rodent neurons and did nothing in humans is enormous, and it includes compounds with better mechanistic stories than this one. Two structural problems drive that gap: animal injury models are acute and uniform while human disease is chronic and heterogeneous, and treatment in animals is typically given at or before the injury, which is rarely possible in a person.
Methylene blue itself demonstrates this risk elsewhere. In Alzheimer disease the tau aggregation story was compelling preclinically and the large human trials of derivatives did not deliver the expected result.
The Dose Window Nobody Should Ignore
The proposed mechanism is concentration-dependent in a way that runs in both directions. At low concentrations methylene blue acts as an electron carrier that may support mitochondrial function. At higher concentrations the same redox activity generates oxidative stress instead.
This means the animal literature does not translate into a simple “more is better” reading, and it is one of the reasons an untested compound cannot be dosed by guesswork for a tissue as unforgiving as the retina. Retinal ganglion cells do not come back.
What Would Have to Happen Next
For any of this to become clinically meaningful, the missing steps are the ordinary ones: safety and dose-finding studies in humans, then controlled trials in a defined eye condition with real visual endpoints such as visual field or acuity, not surrogate imaging measures alone.
The most plausible candidate conditions would be the mitochondrial optic neuropathies, where the mechanism aligns most directly with the disease. None of that work has been done.
A Direct Warning
Nothing here supports self-treating any eye condition. Vision loss from optic neuropathy or glaucoma is permanent, the conditions with established treatments benefit most from starting those treatments early, and time spent on an unproven compound is time not spent on care that works.
Applying methylene blue to the eye directly is a separate and worse idea. Nothing in this literature involves topical ocular use, and the eye is not a place to experiment with a photosensitising dye.
Frequently Asked Questions
Has methylene blue been tested for glaucoma in people?
No. The available research is animal and cell culture work in optic neuropathy models. There are no human trials in glaucoma or any other eye disease.
Why does the animal evidence look so consistent?
Because the mechanism is plausible and the models are reasonably well suited to it. Consistency across independent groups is a real point in favour. It is also true that preclinical neuroprotection consistently fails to translate, so consistency at this stage predicts less than it appears to.
Could taking it orally reach the retina?
Methylene blue does cross into the central nervous system, so some retinal exposure after an oral dose is plausible in principle. What is unknown is whether the concentration reaching retinal ganglion cells resembles anything used in these studies, and whether it would land in the protective part of the dose window or the oxidative part.
What does GAP-43 expression actually mean?
GAP-43 is a protein associated with axonal growth and regeneration. Increased expression after nerve injury suggests a regenerative program has been switched on. It is a promising marker rather than a demonstration of restored vision, and the 2020 study should be read that way.
References
- Methylene blue provides behavioral and metabolic neuroprotection against optic neuropathy. Neurotox Res (2009). PMID 19384599
- Methylene blue protects primary rat retinal ganglion cells from cellular senescence. Invest Ophthalmol Vis Sci (2012). PMID 22661471
- Methylene blue promotes survival and GAP-43 expression of retinal ganglion cells after optic nerve transection. Life Sci (2020). PMID 32961228
- Neuroprotective Effect of Methylene Blue in a Rat Model of Traumatic Optic Neuropathy. Pharmaceuticals (2025). PMID 40573315
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
